Despite extensive randomized controlled trials and meta-analyses assessing the efficacy and safety of EGFR-TKIs for advanced NSCLC patients with EGFR mutations, the optimal therapeutic strategy remains controversial, particularly in light of specific clinicopathological characteristics of patients and emerging evidence [26–35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.